Patents by Inventor Hongchang Qu

Hongchang Qu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220193245
    Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 23, 2022
    Inventors: Tamer COSKUN, Hongchang QU
  • Publication number: 20220127315
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: January 11, 2022
    Publication date: April 28, 2022
    Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
  • Patent number: 11254721
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
  • Publication number: 20220048967
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 17, 2022
    Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
  • Patent number: 11084861
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 10, 2021
    Assignee: Eli Lilly and Company
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
  • Publication number: 20210221865
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.
    Type: Application
    Filed: December 14, 2018
    Publication date: July 22, 2021
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Publication number: 20210032291
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: July 27, 2020
    Publication date: February 4, 2021
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. LAMBRIS, Hongchang Qu, Daniel Ricklin
  • Publication number: 20210032299
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 4, 2021
    Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
  • Publication number: 20200331980
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 22, 2020
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Patent number: 10745442
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 18, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai
  • Publication number: 20190077834
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 10174079
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: January 8, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 9938335
    Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 10, 2018
    Assignee: Eli Lilly and Company
    Inventors: Adam Robert Mezo, Yanyun Chen, Francisco Alcides Valenzuela, Hongchang Qu
  • Publication number: 20170247413
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 31, 2017
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 9630992
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 25, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Publication number: 20160368960
    Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: June 16, 2016
    Publication date: December 22, 2016
    Applicant: Eli Lilly and Company
    Inventors: Adam Robert MEZO, Yanyun CHEN, Francisco Alcides VALENZUELA, Hongchang QU
  • Patent number: 9371365
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: June 21, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu
  • Publication number: 20150203539
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Application
    Filed: February 2, 2015
    Publication date: July 23, 2015
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. LAMBRIS, Hongchang QU
  • Publication number: 20150158915
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: September 7, 2012
    Publication date: June 11, 2015
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin